Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  aldesleukin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 646 for your search:
Start Over
Phase IV Study of Low-Dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CWRU-CHIR-1899, CHIR-MA-99-01, CWRU-010002, NCI-G00-1875, NCT00006864
Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: IRB00024759, R01MH071580, DATR A3-NSS, NCT00352885
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EPC2008-02, NCT01347996
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181203, DARENCA STUDY 2, NCT01339962
Phase II/III Randomized Study of CD8+ TIL/IL-2 for Metastatic Renal Cell Carcinoma (Summary Last Modified 09/95)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AIS-1061-9320, NCI-V95-0689
Phase II/III Randomized Study of Interleukin-2 and Interferon alfa With Versus Without Fluorouracil for Metastatic Renal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 79
Sponsor:
Protocol IDs: FRE-FNCLCC-95009, EU-96026
Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Renal Cell Carcinoma --- A Modified Group C Study (Summary Last Modified 04/88)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor:
Protocol IDs: NCI-C87-0001, AECM-8706153, CHNMC-COH-7077, CMGH-8756-S-87A, CWRCC-0987188, DUMC-7988710, FCCC-88982, IDB-MGC-RENAL/RAND, JHOC-87092507, MDA-DM-87059, UAC-345, UCCRC-4998, UPCC-1887, UUMC-2056, VRCC-CHRMS-8831, WSU-C-70387, YALE-HIC-4454, C87-0001
Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Malignant Melanoma --- A Modified Group C Study (Summary Last Modified 04/88)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor:
Protocol IDs: NCI-C87-0002, AECM-8706152, CHNMC-COH-7075, CMGH-8755-S-87A, CWRCC-0787137, DUMC-7958710, IDB-MGC-MEL/RAND, JHOC-87092508, MDA-DM-87056, UAC-343, UCCRC-4985, UKMC-8800110, UPCC-1687, UUMC-2055, VRCC-CHRMS-8832, WSU-C-70487, YALE-HIC-4455, C87-0002
Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Carcinoma of the Colon (Summary Last Modified 01/88)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: UCCRC-4973A, NCI-V87-0310
Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Malignant Melanoma (Summary Last Modified 01/88)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: UCCRC-4973B, NCI-V87-0311
Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Renal Cell Carcinoma (Summary Last Modified 01/88)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: UCCRC-4973C, NCI-V87-0312
Phase II/III Adoptive Immunotherapy for Metastatic Renal Cell Carcinoma: Systemic IL-2 plus IL-2-Activated/Periodate-Treated Cells (Summary Last Modified 11/90)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 21 to 70
Sponsor:
Protocol IDs: NYH-1088-350CRC, NCI-V88-0417
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Under 30
Sponsor: NCI, Other
Protocol IDs: AHOD0121, CDR0000330135, COG-AHOD0121, NCT00070187
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IL2NHL03, UCLA-0302013, CHIR-IL2NHL03-A01, NCT00045877
Phase III Randomized Study of IL-2 vs Observation Following Autologous Stem Cell Transplantation for Acute Myeloid Leukemia Beyond First Remission
Phase: Phase III
Type: Treatment
Status: Completed
Age: 16 to 60
Sponsor: NCI
Protocol IDs: SWOG-9328, E-S9328
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 22
Sponsor: NCI
Protocol IDs: NCI-2012-01834, 2961, U10CA098543, CDR0000064883, COG-2961, CCG-2961, NCT00002798
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 10 to 70
Sponsor: NCI, Other
Protocol IDs: ID95-196, P30CA016672, MDA-ID-95196, MDA-DM-95196, NCI-G96-1089, CDR0000065188, NCT00002882
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 25
Sponsor: Other
Protocol IDs: CDR0000065406, RPCI-DS-96-48, NCI-G97-1152, NCT00002945
Phase III Randomized Study of Interleukin-2 With or Without Histamine Dihydrochloride in Patients with Stage IV Malignant Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: MAXIM-US-M01, NCI-V98-1382
Methylphenidate in Treating Patients With Melanoma
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066161, E-2Z96, NCI-P98-0130, NCT00003266
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
Phase: Phase III
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: J9726 CDR0000066427, P30CA006973, P01CA015396, JHOC-97080106, JHOC-9726, NCI-V98-1453, NCT00003414
Start Over